Insight Molecular Diagnostics Inc. (IMDX) Max Pain Analysis
Max pain is the strike price where aggregate option buyer payout is minimized at expiration. It represents the price at which option writers retain the most premium.
Insight Molecular Diagnostics Inc. (IMDX) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $136.9M, listed on NASDAQ, employing roughly 46 people, carrying a beta of 1.63 to the broader market. OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. Led by Joshua Riggs, public since 2015-12-30.
Snapshot as of May 15, 2026.
- Spot Price
- $6.37
- Total OI
- 1.8K